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Abstract
Background: Transmitted HIV-1 drug resistance (TDR) is an ongoing public health problem, representing 10–20% of new
HIV infections in many geographic areas. TDR usually arises from two main sources: individuals on antiretroviral therapy
(ART) who are failing to achieve virologic suppression, and individuals who acquired TDR and transmit it while still ART-
naı ¨ve. TDR rates can be impacted when novel antiretroviral medications are introduced that allow for greater virologic
suppression of source patients. Although several new HIV medications were introduced starting in late 2007, including
raltegravir, maraviroc, and etravirine, it is not known whether the prevalence of TDR was subsequently affected in 2008–
2009.
Methodology/Principal Findings: We performed population sequence genotyping on individuals who were diagnosed
with acute or early HIV (,6 months duration) and who enrolled in the Options Project, a prospective cohort, between 2002
and 2009. We used logistic regression to compare the odds of acquiring drug-resistant HIV before versus after the arrival of
new ART (2005–2007 vs. 2008–2009). From 2003–2007, TDR rose from 7% to 24%. Prevalence of TDR was then 15% in 2008
and in 2009. While the odds of acquiring TDR were lower in 2008–2009 compared to 2005–2007, this was not statistically
significant (odds ratio 0.65, 95% CI 0.31–1.38; p=0.27).
Conclusions: Our study suggests that transmitted drug resistance rose from 2003–2007, but this upward trend did not
continue in 2008 and 2009. Nevertheless, the TDR prevalence in 2008–2009 remained substantial, emphasizing that
improved management strategies for drug-resistant HIV are needed if TDR is to be further reduced. Continued surveillance
for TDR will be important in understanding the full impact of new antiretroviral medications.
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Introduction
Transmitted drug-resistant (TDR) HIV is an ongoing public
health challenge, affecting approximately 7–21% of new HIV
infections in the United States and Europe [1–6]. Understanding
current TDR patterns can help clinicians assess the importance of
genotyping antiretroviral therapy (ART)-naı ¨ve patients, inform the
selection of ART regimens, and anticipate trends that may affect
our future ability to effectively treat the HIV epidemic with
existing ART agents.
There are two important sources of TDR: (1) persons who
develop drug resistance mutations while on ART and subsequently
transmit HIV and (2) persons who acquire TDR mutations during
initial infection and maintain the mutations in the absence of ART
until they transmit HIV. If TDR trends are driven primarily by
persons with drug-resistant HIV who are viremic despite taking
ART, changes in ART that achieve better suppression of drug-
resistant HIV should rapidly decrease TDR rates. In contrast, if
TDR is driven more by ART-naı ¨ve individuals, the effects of novel
therapies should be minimal or delayed, at least during the initial
period that these drugs become widely available.
Treatment options for patients with drug-resistant HIV changed
dramatically from 2007–2008. Boosted darunavir and etravirine
both showed strong efficacy in clinical trials [7–10], and two
medications representing novel ART classes—raltegravir and
maraviroc [11,12]—became widely available in the United States
and particularly in San Francisco, aided by universal ART access
programs.
Although the full clinical impact of these new drugs remains
undefined, emerging data suggest that the remarkable efficacy
displayed in clinical trials—particularly with raltegravir [13]—is
also being observed in routine care [14]. Consistent with these
reports, investigators in San Francisco recently reported that from
2004–2008, the city-wide virologic suppression rate improved
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population-level HIV risk measure termed ‘‘community viral
load’’—defined as the mean of all persons’ most recent HIV
plasma RNA levels—and reported that community viral load
declined substantially from 2004–2008 period [15].
A recent mathematical modeling study of TDR in San
Francisco, however, projected that NNRTI drug resistance would
increase over the next five years, primarily from transmission by
ART-naı ¨ve individuals [16]. Thus far, it has not been possible to
compare predictions from this modeling study to actual patient-
based observational data from 2008 and 2009.
The effect of the newest ART medications on the transmission
of drug-resistant HIV is not known. We therefore analyzed HIV
genotypes among patients with acute/early HIV in San Francisco,
with a primary objective of estimating the prevalence of TDR in
an urban setting with historically high levels of drug resistance
[17]. Our secondary objective was to compare the prevalence of
TDR before and after the introduction of new antiretroviral agents
in late 2007.
Methods
Ethics statement
The Committee on Human Research (CHR) is the institutional
review board for the University of California, San Francisco and
its affiliates, FWA00000068. The CHR approved this study, which
involves human subjects as research subjects, entitled ‘‘The
Options Project: An Observational Study of Individuals Recently
Infected with HIV-1.’’ This study was given approval number
H7429-11471-16, which expires 07 May 2011. All participants
gave informed written consent for participation.
Study population and setting
We studied enrollees in the Options Project (San Francisco
General Hospital, University of California, San Francisco) with
estimated HIV infection dates from 2002–2009. The Options
Project is a cohort study of individuals enrolled within 12 months
of HIV antibody seroconversion (in 2003, this was restricted to
within 6 months of seroconversion). Most participants are referred
by community providers if acute (,1 month) or early (,6 months)
HIV infection is suspected. Remaining participants directly seek
screening, or are referred from community-based organizations
and HIV testing sites. Participants are enrolled if they meet
screening criteria for acute/early HIV that combine clinical
history, serologic testing, and plasma HIV RNA determination as
described previously [18,19]. Briefly, participants were defined as
having acute/early HIV if they met one or more of the following
three criteria: (1) two plasma HIV-1 RNA levels $3,000 copies/
mm
3 with a negative or indeterminate HIV-1 antibody test; (2) a
positive HIV-1 antibody test, with a history of a negative HIV-1
antibody test within the previous 12 months (in 2003, this was
changed to 6 months); or (3) a clinical history suggestive of recent
HIV-1 acquisition, along with a reactive standard HIV-1 antibody
test, but a nonreactive less-sensitive (‘‘de-tuned’’) HIV-1 antibody
test [20,21].
Clinical and laboratory evaluations
Study participants had demographic and behavioral data
collected via standardized interviews by trained counselors. CD4
cell counts and plasma HIV-1 RNA levels were also measured.
HIV-1 population sequence genotypes were determined on all
participants (TRUGENE system, Siemens Healthcare Diagnostics,
Tarrytown, NY) as described previously [22,23]. Initial genotypes
were included for analysis if performed within 90 days of screening
for cohort entry. For individuals who initiated ART during early
HIV infection, genotypes were analyzed only if done within 10
days of initiating ART. Drug resistance was ascertained using
published guidelines [24]. These guidelines optimize the specificity
of TDR classification for epidemiologic studies by including only
mutations that are rarely selected for without drug pressure, and
by excluding common polymorphic mutations.
Statistical methods
The overall prevalence of TDR was calculated by estimated
year of infection, along with exact binomial 95% confidence
intervals. Resistance to each ART class (nucleoside reverse
transcriptase inhibitors [NRTIs], NNRTIs, and PIs) was also
calculated by year.
To compare the odds of TDR before and after new
antiretroviral medications arrived in late 2007, we divided patients
into two groups by estimated dates of HIV infection (2005–2007
vs. 2008–2009). Logistic regression of TDR was performed on this
binary time period predictor. Several other predictors of TDR
were also examined in unadjusted analyses, including age,
injection drug use ,2 months prior to cohort enrollment, sexual
identity (MSM, male non-MSM, or female), and estimated
duration of HIV infection upon specimen collection.
Results
A total of 372 patients enrolled in the Options cohort from
2002–2009 and had baseline genotyping. Overall, 95% were male,
with a median age of 35 years (IQR 30–40 years); 96% were men
who have sex with men (MSM), and 9% used injection drugs. The
median CD4 cell count at diagnosis was 520 cells/mm
3 (IQR 391-
660 cells/mm
3); median plasma HIV RNA level was 59,854
copies/mm
3 (IQR 9,775–404,885 copies/mm
3).
From 2002–2009, 59 of 372 patients (16%) had transmitted
HIV-1 drug resistance mutations. The prevalence of TDR was
19% in 2002, dropped to 7% in 2003, then rose from 2003–2007,
reaching a peak of 24% in 2007 (Fig. 1A). Drug resistance was
then 15% in 2008, and was also 15% in 2009. NRTI resistance
fluctuated substantially, rising from 6% in 2002–2003 to 16% in
2006, then decreasing to 11% in 2009 (Fig. 1B). NNRTI resistance
increased from 5% in 2002–2003 to 13% in 2007, and was 8% in
2009 (Fig. 1C). PI resistance was 15% in 2002, but was lower from
2003–2009, ranging from 4–6% (Fig. 1D).
We examined whether TDR differed before and after the
arrival of new antiretroviral medications in late 2007. From 2008–
2009, 15% (95% CI 9%–25%) of cohort members acquired TDR.
This was lower than the 22% prevalence seen in 2005–2007 (95%
CI 14%–30%), but the confidence intervals around both point
estimates were wide. The odds of TDR was lower in 2008–2009
compared to 2005–2007, but this was not statistically significant
(odds ratio 0.65, 95% CI 0.31–1.38; p=0.27). In unadjusted
analyses, age, sexual identity (MSM, male non-MSM, or female),
duration of HIV infection, and recent injection drug use all had
little association with TDR and did not reach statistical
significance, but confidence intervals were too wide to rule out
the possibility of substantial associations (data not shown).
Discussion
We found that despite the introduction of novel ART agents in
San Francisco starting in late 2007, including raltegravir,
maraviroc, and etravirine, the prevalence of transmitted drug
resistance in 2008–2009 remained substantial and was not
significantly different than in prior years.
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infected with HIV in 2008–2009, after the newest ART medications
arrived. Among patients infected in 2005–2007, Hurt et al. reported a
21% prevalence of TDR in North Carolina, similar to our estimate [1].
Numerous reports exist on TDR trends among persons with chronic
HIV, but the impact of new ART is difficult to assess using these data
as they can reflect HIV acquisition years before HIV diagnosis.
Our finding that TDR remained substantial in 2008–2009
could have multiple explanations. It is unlikely that new ART
medications have inadequate potency given their demonstrated
efficacy in treating drug-resistant HIV [7–10,13,25]. Therefore
one explanation for our findings is that suboptimal engagement in
medical care and/or poor ART adherence could be limiting the
penetration of new ART medications among TDR source
patients, leading to a persistently elevated TDR rate. However,
recent data from San Francisco investigators demonstrates that
virologic suppression is improving, and circulating levels of viremia
are decreasing, arguing against poor engagement in care or poor
adherence as chief explanations for our results [15].
A second explanation of our findings is that a sizeable fraction of
drug-resistant HIV is being transmitted by treatment-naı ¨ve
persons who themselves acquired TDR. Given that several years
typically elapse between HIV infection and diagnosis, ART-naı ¨ve
individuals have ample time to transmit drug resistance mutations
to new recipients. Additionally, persons with early stage HIV are
the least likely to be on ART, yet may be responsible for a large
fraction of forward transmission events [26]. Furthermore, persons
with acute/early HIV may have higher seminal HIV RNA levels,
and thus higher infectivity [27]. In this scenario—where TDR is
largely transmitted by ART-naı ¨ve persons—the effects of novel
ART regimens on TDR rates may be delayed.
The TDR prevalence we observed in recent years differs from
that predicted by the mathematical model of Smith et al. [16], who
had predicted rising NNRTI resistance from 2008–2009. In
contrast, our results suggest a stable or even decreasing prevalence
of transmitted NNRTI resistance in San Francisco. While the
sophisticated aforementioned model provides important insights
into TDR patterns, it did not appear to account for changes in
Figure 1. Annual prevalence of transmitted HIV-1 drug resistance in 372 patients with acute/early HIV, 2002-2009. Prevalence (dot)
and 95% confidence interval (vertical line) of overall transmitted drug resistance (A), NRTI resistance (B), NNRTI resistance (C), and PI resistance (D).
TDR, transmitted drug resistance; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease
inhibitor.
doi:10.1371/journal.pone.0015510.g001
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possibly explaining the differences in results.
Our analysis includes several important limitations. First, our
acute/early HIV cohort is not a representative population-based
sample. As such, our results may not fully reflect the HIV epidemic
in San Francisco, though the demographic characteristics of our
cohort subjects closely mirror those of the San Francisco epidemic
overall. Since our study focused on one geographic area, there are
likely to be differences in TDR rates in other settings, particularly
in resource-limited regions where treatment options differ
substantially. Second, we lack data on the uptake of new ART
medications in San Francisco, information which might best be
obtained through clinical databases of treatment records but which
was not available for this analysis. If the uptake of new ART agents
has been slow, more time may be needed to assess the impact on
TDR. Third, our results should be interpreted with caution given
the wide confidence intervals surrounding the annual estimates for
TDR. Studies with longer duration sampling across broader
geographic areas may allow better comparisons of TDR before
and after the introduction of new ART agents.
Despite these limitations our data provide potential insights into
drug-resistant HIV transmission in a setting with historically high
levels of drug resistance. Despite the arrival of several novel ART
medications beginning in late 2007, the prevalence of TDR
remains substantial at the current time. This emphasizes that early
diagnosis and aggressive treatment strategies for patients with
drug-resistant HIV remain crucial. Continued surveillance will be
essential in fully understanding the impact new ART agents will
have on TDR epidemiology.
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